VolitionRX (VNRX) Stock: Buy, Sell, or Hold?
VNRX - VolitionRX Limited Common Stock
$0.32
-0.02 (-6.94%)
▼
5d:
-9.57%
30d:
-52.68%
90d:
-78.33%
HOLD
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When VNRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VNRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: VNRX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: VNRX is currently trading at $0.32, which is considered oversold relative to its 30-day fair value range of $0.35 to $0.68. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.4) compared to its historical average (0.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VNRX is in a strong downtrend. The price is currently testing key support at $0.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: VNRX scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.57 (+4772.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VNRX is in a strong downtrend. The price is currently testing key support at $0.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: VNRX scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.57 (+4772.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.35 -
$0.68
Company Quality Score
61/100
(BUY)
Volume Confirmation
MODERATE
Confidence Score
85.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (85/100)
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 4772.4% below Wall St target ($16.57)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 45% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-9.6%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.35 -
$0.68
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.32
Resistance Level
$0.46
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.40
Wall Street Target
$16.57
(+4772.4%)
Revenue Growth (YoY)
-2.0%
PE vs Historical
-0.4 vs 0.6
CHEAP
Share & Embed Analysis
Last updated: September 11, 2026 3:29 PM ET
Data refreshes hourly during market hours. Next update: 4:29 PM
Data refreshes hourly during market hours. Next update: 4:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$108 | 50 HOLD |
